Glycated Albumin as a Novel Biomarker for Diabetes in Pregnancy: Current Status and Future Prospect
Keywords:
biomarker, glycated albumin, pregnancy, diabetes mellitus, monitoringAbstract
Glycemic biomarkers are important for diagnosis, monitoring, treatment, and prognostication of diabetes complications. In this rapid review, we focus on the strengths and limitation of selected glycemic biomarkers for monitoring purposes in pregnancy: Hemoglobin A1C, fructosamine, and glycated albumin (GA). We elaborated on the characteristics of each marker, the similarities, and differences. We summarize the review with important evidence on the utility and future prospect of GA beyond glycemic monitoring. In summary, GA is a good tool to address the inherent limitation of A1C as a glycemic biomarker. The elucidation provided in this review is poised to enhance the pragmatic and clinical applicability of various glycemic biomarkers in different settings in routine clinical practice
References
A. Ornoy, M. Becker, L. Weinstein-Fudim, and Z. Ergaz, “Diabetes during pregnancy: A maternal disease complicating the course of pregnancy with long-term deleterious effects on the offspring. a clinical review,†International Journal of Molecular Sciences, vol. 22, no. 6. Multidisciplinary Digital Publishing Institute, pp. 1–38, 15-Mar-2021.
M. I. Maiorino et al., “Effects of continuous glucose monitoringonmetricsofglycemic control in diabetes: A Systematic Review with Meta-analysis of Randomized Controlled Trials,†Diabetes Care, vol. 43, no. 5. American Diabetes Association, pp. 1146–1156, 01-May-2020.
T. Wada et al., “Progesterone inhibits glucose uptake by affecting diverse steps of insulin signaling in 3T3-L1 adipocytes,†Am. J. Physiol. - Endocrinol. Metab., vol. 298, no. 4, pp. 881–888, Apr. 2010.
F. Y. Kuo, K.-C. Cheng, Y. Li, and J.-T. Cheng, “Oral glucose tolerance test in diabetes, the old method revisited,†World J. Diabetes, vol. 12, no. 6, pp. 786–793, Jun. 2021.
H. Chehregosha, M. E. Khamseh, M. Malek, F. Hosseinpanah, and F. Ismail-Beigi, “A View Beyond HbA1c: Role of Continuous Glucose Monitoring,†Diabetes Therapy, vol. 10, no. 3. Springer Healthcare, pp. 853–863, 01-Jun-2019.
V. N. Shah et al., “Relationship between Time-in-Range, HbA1c, and the Glucose Management Indicator in Pregnancies Complicated by Type 1 Diabetes,†Diabetes Technol. Ther., vol. 23, no. 12, pp. 783–790, Nov. 2021.
L. Raets, K. Beunen, and K. Benhalima, “Screening for gestational diabetes mellitus in early pregnancy: What is the evidence?,†Journal of Clinical Medicine, vol. 10, no. 6. Multidisciplinary Digital Publishing Institute, pp. 1–16, 18-Mar-2021.
M. Lemaitre, C. Ternynck, J. Bourry, F. Baudoux, D. Subtil, and A. Vambergue, “Association Between HbA1c Levels on Adverse Pregnancy Outcomes During Pregnancy in Patients With Type 1 Diabetes,†J. Clin. Endocrinol. Metab., vol. 107, no. 3, pp. E1117–E1125, Feb. 2022.
N. Furusyo and J. Hayashi, “Glycated albumin and diabetes mellitus,†Biochimica et Biophysica Acta - General Subjects, vol. 1830, no. 12. Elsevier, pp. 5509–5514, 01-Dec-2013.
F. C. Chume, P. B. Renz, M. K. Hernandez, P. A. C. Freitas, and J.
L. Camargo, “Is there a role for glycated albumin in the diagnosis of gestational diabetes mellitus?,†Endocrine, vol. 72, no. 3, pp. 681–687, Jun. 2021.
X. Liu, N. Wu, and A. Al-Mureish, “A review on research progress in the application of glycosylated hemoglobin and glycated albumin in the screening and monitoring of gestational diabetes,†International Journal of General Medicine, vol. 14. Dove Medical Press Ltd, pp. 1155–1165, 2021.
T. Kohzuma, X. Tao, and M. Koga, “Glycated albumin as biomarker: Evidence and its outcomes,†J. Diabetes Complications, vol. 35, no. 11, p. 108040, Nov. 2021.
M. Zendjabil, “Glycated albumin,†Clinica Chimica Acta, vol. 502. Elsevier, pp. 240–244, 01-Mar-2020.
K. Hashimoto, “Indicators of glycemic control in patients with gestational diabetes mellitus and pregnant women with diabetes mellitus,†World J. Diabetes, vol. 6, no. 8, p. 1045, Jul. 2015.
A. Sweeting, J. Wong, H. R. Murphy, and G. P. Ross, “A Clinical Update on Gestational Diabetes Mellitus,†Endocrine Reviews, vol. 43, no. 5. Oxford Academic, pp. 763–793, 26-Sep-2022.
S. Suehara, M. Waguri, K. Wakabayashi, and I. Nakanishi, “Frequency and congenital anomaly of pregnant women with diabetes mellitus and gestational diabetes mellitus,†Diabetes and Pregnancy, vol. 10, pp. 104–108, 2010.
Y. Saisho et al., “Beta cell dysfunction and its clinical significance in gestational diabetes,†Endocr. J., vol. 57, no. 11, pp. 973–980, 2010.
S. Knapp, “Diabetes and infection: Is there a link? - A mini-review,†Gerontology, vol. 59, no. 2. S. Karger AG, pp. 99–104, 01-Feb-2013.
E. Danese, M. Montagnana, A. Nouvenne, and G. Lippi, “Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes,†in Journal of Diabetes Science and Technology, 2015, vol. 9, no. 2, pp. 169–176.
E. Danese, M. Montagnana, A. Nouvenne, and G. Lippi, “Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes,†in Journal of Diabetes Science and Technology, 2015, vol. 9, no. 2, pp. 169–176.
V. Gounden, M. Ngu, C. Anastasopoulou, and I. Jialal, “Fructosamine,†StatPearls, Aug. 2023.
M. M. Agarwal, G. S. Dhatt, Y. Othman, and M. R. Ljubisavljevic, “Gestational diabetes: An evaluation of serum fructosamine as a screening test in a high-risk population,†Gynecol. Obstet. Invest., vol. 71, no. 3, pp. 207–212, Apr. 2011.
A. Ekhzaimy et al., “Fructosamine as an Index of Short-Term Glycemic Control in Pregnant Women with Diabetes: Before, During and After Ramadan,†Int. J. Womens. Health, vol. 14, pp. 435–444, 2022.
E. Bernier et al., “Trimester-Specific Serum Fructosamine in Association with Abdominal Adiposity, Insulin Resistance, and Inflammation in Healthy Pregnant Individuals,†Nutrients, vol. 14, no. 19, p. 3999, Oct. 2022.
V. Gingras, S. L. Rifas-Shiman, K. M. Switkowski, E. Oken, and M. F. Hivert, “Mid-pregnancy fructosamine measurement—Predictive value for gestational diabetes and association with postpartum glycemic indices,†Nutrients, vol. 10, no. 12, p. 2003, Dec. 2018.
S. Ayyappan, S. Philips, C. K. Kumar, V. Vaithiyanandane, and C. Sasikala, “Serum fructosamine a better indicator than glycated hemoglobin for monitoring gestational diabetes mellitus,†J. Pharm. Bioallied Sci., vol. 7, no. Suppl 1, pp. S32–S34, Apr. 2015.
T. A. Pramodkumar et al., “1,5 Anhydroglucitol in gestational diabetes mellitus,†J. Diabetes Complications, vol. 33, no. 3, pp. 231–235, Mar. 2019.
T. Ninomiya, “Diabetes mellitus and dementia,†Current Diabetes Reports, vol. 14, no. 5. Current Medicine Group LLC 1, pp. 1–9, 13-Mar-2014.
T. Ohara et al., “Glucose tolerance status and risk of dementia in the community: The Hisayama Study,†Neurology, vol. 77, no. 12, pp. 1126–1134, Sep. 2011.
A. M. Rawling
s et al., “The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia: The ARIC study,†Diabetes Care, vol. 42, no. 7, pp. 1248–1264, Jul. 2019.
N. Mukai et al., “Alternative measures of hyperglycemia and risk of Alzheimer’s disease in the community: The hisayama study,†J. Clin. Endocrinol. Metab., vol. 102, no. 8, pp. 3002–3010, Aug. 2017.
T. Ohara et al., “Elevated serum glycated albumin and glycated albumin : hemoglobin A1c ratio were associated with hippocampal atrophy in a general elderly population of Japanese: The Hisayama Study,†J. Diabetes Investig., vol. 11, no. 4, pp. 971–979, Jul. 2020.
A. Hidaka et al., “Plasma C-peptide and glycated albumin and subsequent risk of cancer: From a large prospective case-cohort study in Japan,†Int. J. Cancer, vol. 144, no. 4, pp. 718–729, Feb. 2019.
K. Ozasa et al., “Glucose intolerance and colorectal cancer risk in a nested case-control study among Japanese people,†J. Epidemiol., vol. 15, no. SUPPL. 2, pp. S180–S184, 2005.
M. T. Marrone, E. Selvin, J. R. Barber, E. A. Platz, and C. E. Joshu, “Hyperglycemia, classified with multiple biomarkers simultaneously in men without diabetes, and risk of fatal prostate cancer,†Cancer Prev. Res., vol. 12, no. 2, pp. 103–112, Feb. 2019.
Downloads
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
